Ann: Phase I Clinical Trial of R327 I.V. - 6000mg Complete, page-16

Yea I have been wondering about the phase 2 trial too.

They may trial it in patients with suspected or known bacteraemia (bacteria in the blood) who have not yet developed sepsis (the widespread inflammatory reaction in response to the blood infection). And run pre- and post-treatment blood cultures.

After all, I believe the company material stating that sepsis is the target of the IV product is probably a simplification. It's really the bacteraemia associated with sepsis which Recce 327 will hopefully be licensed for. Sepsis patients would still require a raft of other therapies to moderate the out-of-control immune system.